References
Key articles
Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013 Jun 20;368(25):2402-14. Abstract
Trimarchi H, Barratt J, Cattran DC, et al; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017 May;91(5):1014-21. Abstract
Barratt J, Feehally J. Primary IgA nephropathy: new insights into pathogenesis. Semin Nephrol. 2011 Jul;31(4):349-60. Abstract
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-S276.Full text Abstract
Lv J, Zhang H, Wong MG, et al; TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017 Aug 1;318(5):432-42. Abstract
Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015 Dec 3;373(23):2225-36.Full text Abstract
Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol. 2004 May;24(3):256-68. Abstract
Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol. 2004 May;24(3):256-68. Abstract
Reference articles
1. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013 Jun 20;368(25):2402-14. Abstract
2. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009 Sep;76(5):534-45. Abstract
3. Zeng CH, Le W, Ni Z, et al. A multicenter application and evaluation of the Oxford classification of IgA nephropathy in adult Chinese patients. Am J Kidney Dis. 2012 Nov;60(5):812-20. Abstract
4. Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014 Oct;86(4):828-36.Full text Abstract
5. Herzenberg AM, Fogo AB, Reich HN, et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int. 2011 Aug;80(3):310-7. Abstract
6. Trimarchi H, Barratt J, Cattran DC, et al; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017 May;91(5):1014-21. Abstract
7. Haas M, Verhave JC, Liu ZH, et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol. 2017 Feb;28(2):691-701. Abstract
8. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005 Jul;16(7):2088-97. Abstract
9. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002 Sep 5;347(10):738-48. Abstract
10. Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018 Sep;38(5):435-42.Full text Abstract
11. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011 Feb;26(2):414-30.Full text Abstract
12. Kwon CS, Daniele P, Forsythe A, et al. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of Immunoglobulin A nephropathy. J Health Econ Outcomes Res. 2021;8(2):36-45.Full text Abstract
13. Knoppova B, Reily C, King RG, et al. Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment. J Clin Med. 2021 Sep 29;10(19):4501.Full text Abstract
14. Penfold RS, Prendecki M, McAdoo S, et al. Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018;11:137-48.Full text Abstract
15. Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017 Apr 3;12(4):677-86.Full text Abstract
16. Gharavi AG, Yan Y, Scolari F, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000 Nov;26(3):354-7. Abstract
17. Bisceglia L, Cerullo G, Forabosco P, et al. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet. 2006 Dec;79(6):1130-4.Full text Abstract
18. Paterson AD, Liu XQ, Wang K, et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol. 2007 Aug;18(8):2408-15.Full text Abstract
19. Karnib HH, Sanna-Cherchi S, Zalloua PA, et al. Characterization of a large Lebanese family segregating IgA nephropathy. Nephrol Dial Transplant. 2007 Mar;22(3):772-7.Full text Abstract
20. Kiryluk K, Li Y, Sanna-Cherchi S, et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 2012;8(6):e1002765.Full text Abstract
21. Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011 Mar 13;43(4):321-7.Full text Abstract
22. Feehally J, Farrall M, Boland A, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol. 2010 Oct;21(10):1791-7.Full text Abstract
23. Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014 Nov;46(11):1187-96.Full text Abstract
24. Pouria S, Feehally J. Glomerular IgA deposition in liver disease. Nephrol Dial Transplant. 1999 Oct;14(10):2279-82. Abstract
25. Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis. 1987 Mar;9(3):183-90. Abstract
26. Beaufils H, Jouanneau C, Katlama C, et al. HIV-associated IgA nephropathy - a post-mortem study. Nephrol Dial Transplant. 1995;10(1):35-8. Abstract
27. Katz A, Bargman JM, Miller DC, et al. IgA nephritis in HIV-positive patients: a new HIV-associated nephropathy? Clin Nephrol. 1992 Aug;38(2):61-8. Abstract
28. Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med. 1992 Sep 3;327(10):702-6.Full text Abstract
29. Meadow SR, Scott DG. Berger disease: Henoch-Schönlein syndrome without the rash. J Pediatr. 1985 Jan;106(1):27-32. Abstract
30. Deltas C, Pierides A, Voskarides K. Molecular genetics of familial hematuric diseases. Nephrol Dial Transplant. 2013 Dec;28(12):2946-60.Full text Abstract
31. Tomino Y. Pathogenesis of IgA nephropathy. Contrib Nephrol. 2007;157:1-7. Abstract
32. Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999 Jul;104(1):73-81. Abstract
33. Barratt J, Feehally J. Primary IgA nephropathy: new insights into pathogenesis. Semin Nephrol. 2011 Jul;31(4):349-60. Abstract
34. Lafayette RA, Kelepouris E. Immunoglobulin A nephropathy: advances in understanding of pathogenesis and treatment. Am J Nephrol. 2018;47 Suppl 1:43-52.Full text Abstract
35. Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 2018 May;33(5):763-77.Full text Abstract
36. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000 Aug;36(2):227-37. Abstract
37. Galla JH. IgA nephropathy. Kidney Int. 1995 Feb;47(2):377-87. Abstract
38. Murugapandian S, Mansour I, Hudeeb M, et al. Epidemiology of glomerular disease in southern Arizona: review of 10-year renal biopsy data. Medicine (Baltimore). 2016 May;95(18):e3633.Full text Abstract
39. Narva AS. The spectrum of kidney disease in American Indians. Kidney Int Suppl. 2003 Feb;(83):S3-7.Full text Abstract
40. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-S276.Full text Abstract
41. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005 Sep-Oct;18(5):503-12. Abstract
42. Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001 Apr 15;110(6):434-7. Abstract
43. Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy. Semin Nephrol. 2004 May;24(3):197-217. Abstract
44. Davin JC, Ten Berge IT, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis? Kidney Int. 2001 Mar;59(3):823-34. Abstract
45. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997 Jun;29(6):829-42. Abstract
46. Iseki K, Miyasoto F, Uehara H, et al. Outcome study of renal biopsy patients in Okinawa, Japan. Kidney Int. 2004 Sep;66(3):914-9. Abstract
47. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004 Sep;66(3):920-3. Abstract
48. Hasbargen JA, Copley JB. Utility of skin biopsy in the diagnosis of IgA nephropathy. Am J Kidney Dis. 1985 Aug;6(2):100-2. Abstract
49. Brenner BM, Levine SA. Brenner and Rector's the kdney. 7th ed. Boston, MA: Saunders; 2007:3072.
50. Boyd JK, Cheung CK, Molyneux K, et al. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 2012 May;81(9):833-43. Abstract
51. Floege J, Feehally J. Treatment of IgA nephropathy and Henoch-Schönlein nephritis. Nat Rev Nephrol. 2013 Jun;9(6):320-27. Abstract
52. Rosselli JL, Thacker SM, Karpinski JP, et al. Treatment of IgA nephropathy: an update. Ann Pharmacother. 2011 Oct;45(10):1284-96. Abstract
53. Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 2006 Jun;69(11):1939-44. Abstract
54. Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006 Jun;69(11):1934-8. Abstract
55. Praga M, Gutiérrez E, González E, et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003 Jun;14(6):1578-83. Abstract
56. Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001 Jul;38(1):18-25. Abstract
57. Brenner BM, Levine SA. Brenner and Rector's the kidney. 7th ed. Boston, MA: Saunders; 2007:3072.
58. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999 Mar 13;353(9156):883-7. Abstract
59. Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004 Jan;15(1):157-63. Abstract
60. Lv J, X, Wang H. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol. 2012 Jun;23(6):1108-16. Abstract
61. Natale P, Palmer SC, Ruospo M, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020 Mar 12;3:CD003965.Full text Abstract
62. Lv J, Zhang H, Wong MG, et al; TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017 Aug 1;318(5):432-42. Abstract
63. Hou JH, Le WB, Chen N, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis. 2017 Jun;69(6):788-95.Full text Abstract
64. Xie Y, Chen X, Nishi S, et al. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int. 2004 Apr;65(4):1135-44. Abstract
65. Reid S, Cawthon PM, Craig JC, et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD003962. Abstract
66. Chen Y, Tang Z, Wang Q, et al. Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy. Am J Nephrol. 2007;27(2):170-75. Abstract
67. Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001 Oct;38(4):736-43. Abstract
68. Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015 Dec 3;373(23):2225-36.Full text Abstract
69. Liu LL, Wang LN, Liu LL, et al. Omega-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. Clin Nephrol. 2012 Feb;77(2):119-25. Abstract
70. Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 2006 Jun;69(11):1939-44. Abstract
71. Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol. 2004 May;24(3):256-68. Abstract
72. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002 Jan;13(1):142-8. Abstract
73. Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol. 2004 May;24(3):256-68. Abstract
74. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002 Jan;13(1):142-8. Abstract
75. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 Oct 8;383(15):1436-46.Full text Abstract
76. Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021 Jul;100(1):215-24.Full text Abstract
77. US National Library of Medicine. ClinicalTrials.gov. A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic kidney disease. Jan 2022 [internet publication].Full text
78. Smerud HK, Bárány P, Lindström K, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant. 2011 Oct;26(10):3237-42.Full text Abstract
79. Selvaskandan H, Cheung CK, Muto M, et al. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol. 2019 May;23(5):577-88.Full text Abstract
80. Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017 May 27;389(10084):2117-27. Abstract
81. US National Library of Medicine. ClinicalTrials.gov. A randomized, multicenter, double-blind, parallel-group, active-control study of the efficacy and safety of sparsentan for the treatment of Immunoglobulin A nephropathy. June 2021 [internet publication].Full text
82. US National Library of Medicine. ClinicalTrials.gov. A phase 3, randomized, double-blind, placebo-controlled study of atrasentan in patients with IgA nephropathy at risk of progressive loss of renal function. Oct 2021 [internet publication].Full text
83. US National Library of Medicine. ClinicalTrials.gov. A randomized, double-blind, placebo-controlled, phase 3 study of the safety and efficacy of OMS721 in patients with Immunoglobulin A (IgA) nephropathy (ARTEMIS - IGAN). May 2019 [internet publication].Full text
84. US National Library of Medicine. ClinicalTrials.gov. A phase 2, randomized, double-blind, placebo-controlled study of cemdisiran in adult patients with IgA nephropathy. Dec 2021 [internet publication].Full text
85. US National Library of Medicine. ClinicalTrials.gov. An open-label phase 2a clinical study to evaluate the effectiveness and safety of IONIS-FB-LRx, an antisense inhibitor of complement factor B, in adult subjects with primary IgA nephropathy. Oct 2021 [internet publication].Full text
86. Gutiérrez E, Carvaca-Fontán F, Luzardo L, et al. A personalized update on IgA nephropathy: a new vision and new future challenges. Nephron. 2020;144(11):555-71.Full text Abstract
87. US National Library of Medicine. ClinicalTrials.gov. An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients. July 2021 [internet publication].Full text
88. US National Library of Medicine. ClinicalTrials.gov. A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients. Dec 2021 [internet publication].Full text
89. Harris CL, Pouw RB, Kavanagh D, et al. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol. 2018 Oct;102:89-119.Full text Abstract
90. US National Library of Medicine. ClinicalTrials.gov. A phase 1/2, multicenter trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BION-1301 in healthy volunteers and adults with IgA nephropathy. Dec 2021 [internet publication].Full text
91. US National Library of Medicine. ClinicalTrials.gov. A multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy and safety of VIS649 in participants with Immunoglobulin A (IgA) nephropathy. Sept 2021 [internet publication].Full text
92. Galla JH. IgA nephropathy. Kidney Int. 1995 Feb;47(2):377-87. Abstract
93. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000 Aug;36(2):227-37. Abstract
94. Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019 Jul 1;179(7):942-52.Full text Abstract
95. Beerman I, Novak J, Wyatt RJ, et al. The genetics of IgA nephropathy. Nat Clin Pract Nephrol. 2007 Jun;3(6):325-38. Abstract
96. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005 Jul;16(7):2088-97. Abstract
Use of this content is subject to our disclaimer